Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05937685 · ClinicalTrials.gov registry record · NA

Reducing Blood Pressure in Patients With High Cardiovascular Risk

A NA study of Hypertension and Stroke, sponsored by University of Southern California.

Recruiting
Registry status
NA
Development phase
546
Enrollment target
4
Study locations

NCT05937685: Recruiting NA study of Hypertension and Stroke, sponsored by University of Southern California.

NCT05937685 is a NA study of Hypertension and Stroke that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 546 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (84% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05937685, a NA study of Hypertension and Stroke, is actively recruiting participants, sponsored by University of Southern California.

RECRUITING
Registry status
NA
Development phase
546 participants
Enrollment target
4
Study locations

Study Summary

BP-REACH is a study of a team-based (pharmacist and health coach) program for lowering blood pressure for people with a prior stroke or heart attack in the Los Angeles Department of Health Services healthcare system. The goal of this clinical trial is to test if this team based program is better at helping people reduce their blood pressure than usual care for people with prior heart attack or stroke. The main questions it aims to answer are: * Do people in the REACH BP program have lower blood pressure at 12 months compared to those getting usual care? * Do people in the REACH BP program have better Life's Essential 8 scores and patient experience compared to those getting usual care?

Primary Outcome

Collected by study staff using blood pressure monitor

Interventions

  • BEHAVIORAL BP REACH Intervention

Study Locations (4)

California

  • Rancho Los Amigos National Rehabilitation Center - Downey
  • LA General Medical Center - Los Angeles
  • Olive View Medical Center - Sylmar
  • Harbor UCLA Medical Center - Torrance

Trial Details

FieldValue
Enrollment Target 546 participants
Start Date 2023-09-01
Est. Completion 2026-07
Phase NA
University of Southern California

617 total trials

What NCT05937685 shows while recruiting

NCT05937685 is an interventional study that assigns participants to a tested intervention. The registered 546 participants enrollment target is mid-sized for trials with a published cap, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (84% lower).

The record links to 3 conditions, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which BP REACH Intervention is the first listed.

NCT05937685 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05937685 about?

NCT05937685 is a clinical study titled "Reducing Blood Pressure in Patients With High Cardiovascular Risk". BP-REACH is a study of a team-based (pharmacist and health coach) program for lowering blood pressure for people with a prior stroke or heart attack in the Los Angeles Department of Health Services healthcare system. The goal of this clinical trial is to test if this team based program is better at...

What is the current status of trial NCT05937685?

This trial is currently recruiting. It is a NA study. The enrollment target is 546 participants. The study started on 2023-09-01. Estimated completion is 2026-07.

What conditions does trial NCT05937685 study?

This clinical trial studies the following conditions: Hypertension, Stroke, Myocardial Infarction.

What interventions are being tested in trial NCT05937685?

The interventions under investigation include: BP REACH Intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT05937685?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05937685 being conducted?

This trial has 4 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05937685's enrollment target sits among peer trials

546 108th of 470 higher than 363 of 470 other Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03572374 · 546 participants · NA

    Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job

  • NCT06416150 · 546 participants · NA

    Reducing Urban Cervical Cancer Disparities

  • NCT06850922 · 546 participants · Phase 1

    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

  • NCT04553523 · 545 participants · NA

    Hydrus® Microstent New Enrollment Post-Approval Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05937685, the US trial registry maintained by the National Library of Medicine. NCT05937685 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.